Gain Therapeutics Q2 2024 GAAP EPS $(0.42) Misses $(0.20) Estimate
Portfolio Pulse from Benzinga Newsdesk
Gain Therapeutics (NASDAQ:GANX) reported a Q2 2024 GAAP EPS of $(0.42), missing the analyst consensus estimate of $(0.20) by 110%. This represents a 32.26% improvement over the $(0.62) loss per share from the same period last year.
August 08, 2024 | 11:49 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Gain Therapeutics reported a Q2 2024 GAAP EPS of $(0.42), missing the analyst consensus estimate of $(0.20) by 110%. Despite the miss, the loss per share improved by 32.26% compared to the same period last year.
The significant miss on earnings estimates is likely to negatively impact the stock price in the short term. However, the year-over-year improvement in losses may provide some support.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100